This clinical trial provided the first evidence for the effectiveness of PARP inhibitors in the treatment of pancreatic cancer and subsequently resulted in the FDA approval of Olaparib for the treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinomas. Here, PARP1 is linked to pancreatic neoplasm.